After one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.
Dr Hansen will be succeeded by Dr Russell Greig, who will also become a permanent representative of Greig Biotechnology Global Consulting.
Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman.
To date he has served in various roles during his 28-year career at GlaxoSmithKline, where he most recently served as president for both GSK Pharmaceuticals and SROne, the venture arm of GSK.
Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time.
“Russell knows the company extremely well and will be an important asset during the next months.”